Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
United States Minor Outlying Islands residents can access FDA-approved GLP-1 medications through licensed telehealth providers at the most affordable cost possible. Whether you are in a major city or a smaller community, our physicians and support staff help navigate insurance coverage and manufacturer savings programs to reduce your out-of-pocket expenses.
Licensed physicians in our network prescribe semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) following the evidence-based dose-escalation schedules established in the STEP 1 and SURMOUNT-1 randomized controlled trials published in the New England Journal of Medicine.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 6, 2026
United States Minor Outlying Islands allows licensed physicians to prescribe GLP-1 medications through telehealth, creating a more affordable pathway than traditional specialist visits. All UM-licensed providers in our network are equipped to handle insurance billing, prior authorization support, and savings program enrollment.
Our telehealth platform connects GLP-1 patients with licensed physicians in every city statewide. Find your city below to get started.
The following landmark trials published in the New England Journal of Medicine establish the efficacy and safety profile of FDA-approved GLP-1 medications:
United States Minor Outlying Islands authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in United States Minor Outlying Islands.
FDA-approved GLP-1 prescriptions are accessible from any city through our board-certified telehealth network. Find your city below to get started.
Local weight loss and GLP-1 providers serving the United States Minor Outlying Islands area, based on Google Business listings.
Kailua-Kona, HI
(808) 327-9609
5/5 ★ (14 reviews)
Visit website →30 E Lipoa St SUITE 4 102, Kihei, HI 96753
(808) 808-1240
5/5 ★ (3 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes, for many patients. Telehealth eliminates office visit costs, and many United States Minor Outlying Islands insurance plans cover GLP-1 medications for FDA-approved indications. Manufacturer savings programs can reduce costs to as little as $0-25 per month for eligible patients with commercial insurance.
Many private insurance plans in United States Minor Outlying Islands cover GLP-1 medications when prescribed for FDA-approved indications. Coverage depends on your specific plan and medication. Our UM-licensed physicians provide documentation to support insurance coverage and prior authorization when needed.
Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) offer savings card programs for commercially insured United States Minor Outlying Islands patients that can significantly reduce out-of-pocket costs. Patient assistance programs are also available for those who qualify based on income.
Typically, yes. Telehealth eliminates specialist referral costs, office visit copays, and the time and transportation expense of in-person visits. Many United States Minor Outlying Islands patients find the total cost of telehealth GLP-1 care to be equal to or lower than traditional in-person pathways.
Adults in United States Minor Outlying Islands with a BMI ≥30, or ≥27 with a weight-related condition, are typically eligible for GLP-1 therapy. Eligibility for savings programs depends on insurance status and income. Your physician will help identify the most cost-effective pathway for your specific situation.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
